中国国际金融股份有限公司 关于 山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票 之 发行保荐书 保荐机构 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年六月 关于山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票之发行保荐书 3-1-1 第一节 本次证券发行基本情况 一、保荐机构名称 中国国际金融股份有限公司。 二、具体负责本次推荐的保荐代表人 伍韵：于 2021 年 3 月取得保荐代表人资格，曾担任心脉医疗（688016.SH）向特定 对象发行股票项目签字保荐代表人，并曾参与复星医药（600196.SH）非公开发行项目、 万事利（301066.SZ）创业板 IPO 项目等。在保荐业务执业过程中严格遵守《保荐办法》 等相关规定，执业记录良好。 王峰：于 2022 年 9 月取得保荐代表人资格，未曾担任过已完成的首发、再融资、 转板项目签字保荐代表人，曾参与山东百诺医药股份有限公司创业板 IPO 项目、青岛 有屋智能家居科技股份有限公司 A 股 IPO 项目、同力水泥（000885.SZ，2018 年更名为 城发环境）重大资产重组、云南 ...

证券代码：600789 证券简称：鲁抗医药 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年六月 上海证券交易所： 贵所于 2025 年 5 月 9 日出具的上证上审（再融资）〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特定对象发行股票申请文件的审核问询函》（以下简称"问询函"） 已收悉，山东鲁抗医药股份有限公司（简称"鲁抗医药"、"发行人"、"公司"）、中国国 际金融股份有限公司（简称"保荐机构"、"中金公司"）、和信会计师事务所（特殊普通 合伙）（简称"申报会计师"）、北京市通商律师事务所（简称"发行人律师"）等相关方 对问询函所列问题进行了逐项落实、核查，现对问询函问题回复如下，请予审核。 如无特别说明，本回复中的简称或名词释义与募集说明书（申报稿）中的相同。本 回复中的字体代表以下含义： | 问询函所列问题 | 黑体（不加粗） | | --- | --- | | 对问题的回答 | 宋体（不加粗） | | 对募集说明书等申请文件的修改、补充 | 楷体（加粗 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2025—029 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的审核问询函 公司收到《问询函》后，会同相关中介机构就《问询函》所列问题进行了认 真研究和逐项落实，根据相关要求对《问询函》有关问题进行了说明和论证，同 时对募集说明书等申请文件的部分内容进行了相应补充和修订，具体内容详见公 司同日在上海证券交易所网站（www.sse.com.cn）披露的《关于山东鲁抗医药股 份有限公司向特定对象发行股票申请文件的审核问询函的回复》等文件。 公司本次向特定对象发行股票事项尚需通过上交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册的批复后方可实施，最终能 否通过上交所审核并获得中国证监会同意注册的批复及其时间尚存在不确定性。 公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注意投资 风险。 特此公告。 山东鲁抗医药股份有限公司董事会 2025 年 6 月 18 日 1 回复及募集说明书等申请文件更新的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、 ...

Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. is preparing to issue A-shares to specific investors in 2024, with legal opinions provided by Beijing Tongshang Law Firm regarding potential competition with Xinhua Pharmaceutical and the implications for the company [1][2]. Group 1: Company Overview - Shandong Lukang Pharmaceutical primarily engages in the research, production, and sale of pharmaceutical products, including antibiotics, antidiabetic drugs, cardiovascular drugs, and more, with over 500 product specifications [3][4]. - Xinhua Pharmaceutical, also established in 1993, focuses on the development and sale of chemical raw materials and formulations, with a product range that includes analgesics and cardiovascular drugs [4][5]. Group 2: Competition Analysis - There is some overlap in the product offerings of Shandong Lukang Pharmaceutical and Xinhua Pharmaceutical; however, the main products, technologies, and customer bases are significantly different, indicating no substantial adverse impact from competition [6][7]. - The revenue and gross profit from overlapping products between the two companies are relatively low, with Xinhua's overlapping products accounting for 3.08% to 5.69% of Lukang's main business revenue during the reporting period [11][12]. Group 3: Commitment to Avoid Competition - The controlling shareholder, Hualu Group, has issued a commitment to avoid any competition that could adversely affect Shandong Lukang Pharmaceutical, ensuring that both companies operate independently [14][15]. - Hualu Group has established internal management systems to ensure compliance with the commitment to avoid competition, and there have been no violations reported [18][19]. Group 4: Fundraising and Project Impact - The fundraising projects, including the construction of a high-end formulation intelligent manufacturing workshop and new drug research, are aimed at expanding existing business operations and will not introduce new competition [13][14]. - The proposed projects are aligned with the company's current business scope and are expected to enhance production capacity without creating significant competitive overlap with Xinhua Pharmaceutical [13][14].

Core Viewpoint - The report discusses the financial performance and operational changes of Shandong Lukang Pharmaceutical Co., Ltd., highlighting significant growth in sales net profit margin and the impact of asset disposal on profitability [1][11]. Financial Performance - The company's operating revenue for the reporting periods was 562.14 million yuan, 614.67 million yuan, and 623.31 million yuan, with net profits of 13.80 million yuan, 24.62 million yuan, and 40.83 million yuan respectively [1][2]. - The sales net profit margins increased from 2.55% in 2022 to 4.18% in 2023, and further to 6.55% in 2024, primarily due to changes in product structure and asset disposal gains [3][11]. Gross Margin Analysis - The comprehensive gross margins for the reporting periods were 22.19%, 24.65%, and 23.96%, with the main business gross margin contributing significantly to overall profitability [3][4]. - The gross margin for the human medicine segment showed a steady increase, with the formulation drug gross margin rising from 33.68% to 41.46% over the reporting periods [4][5]. Cost Structure - The operating costs for the company were 473.95 million yuan, 463.13 million yuan, and 437.40 million yuan, indicating a controlled cost structure relative to revenue growth [2][6]. - Direct material costs accounted for approximately 75.45% of total revenue, reflecting the significant impact of raw material prices on overall profitability [6][8]. Market Competition and Product Performance - The raw material drug gross margin fluctuated, showing a decline in 2023 due to market competition, followed by a recovery in 2024 [5][9]. - The veterinary medicine segment experienced variable gross margins, influenced by market demand and competition, with margins of 15.66%, 18.16%, and 13.23% over the reporting periods [9][10]. Asset Disposal Impact - The company realized substantial asset disposal gains in 2024, amounting to 283.26 million yuan, significantly boosting net profit and sales net profit margin [9][10]. - The asset disposal was linked to the completion of land storage for the southern plant area, which was part of a strategic relocation initiative [10][11]. Export and Revenue Matching - The customs declaration data matched closely with overseas revenue, with minor discrepancies deemed reasonable due to small sample exports and timing differences [13][14]. - The company’s overseas revenue was diversified across several countries, including the UK, Netherlands, and Egypt, with stable trade and tariff policies [16][17]. Sales Expenses - The sales expense ratios were 8.45%, 9.40%, and 9.11%, significantly lower than the industry average, indicating efficient cost management in sales promotion [19][20]. - The increase in promotional expenses from 2023 was attributed to strategic marketing efforts to enhance product visibility and market share [19].

证券代码：600789 证券简称：鲁抗医药 公告编号：2025—029 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的审核问询函 回复及募集说明书等申请文件更新的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于近期收到上海证券交易 所（以下简称"上交所"）出具的《关于山东鲁抗医药股份有限公司向特定对象 发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕137 号，以下 简称《问询函》），上交所审核机构对公司向特定对象发行股票申请文件进行了 审核，并形成了问询问题。 公司收到《问询函》后，会同相关中介机构就《问询函》所列问题进行了认 真研究和逐项落实，根据相关要求对《问询函》有关问题进行了说明和论证，同 时对募集说明书等申请文件的部分内容进行了相应补充和修订，具体内容详见公 司同日在上海证券交易所网站（www.sse.com.cn）披露的《关于山东鲁抗医药股 份有限公司向特定对象发行股票申请文件的审核问询函的回复》等文件。 公司本次向特定对象发行股 ...

证券代码：600789 证券简称：鲁抗医药 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年六月 上海证券交易所： 请保荐机构核查并发表明确意见。 贵所于 2025 年 5 月 9 日出具的上证上审（再融资）〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特定对象发行股票申请文件的审核问询函》（以下简称"问询函"） 已收悉，山东鲁抗医药股份有限公司（简称"鲁抗医药"、"发行人"、"公司"）、中国国 际金融股份有限公司（简称"保荐机构"、"中金公司"）、和信会计师事务所（特殊普通 合伙）（简称"申报会计师"）、北京市通商律师事务所（简称"发行人律师"）等相关方 对问询函所列问题进行了逐项落实、核查，现对问询函问题回复如下，请予审核。 如无特别说明，本回复中的简称或名词释义与募集说明书（申报稿）中的相同。本 回复中的字体代表以下含义： | 问询函所列问题 | 黑体（不加粗） | | --- | --- | | 对问题的回答 | 宋体（不加粗） | | 对募集说明书等申请 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-028 山东鲁抗医药股份有限公司 关于获得药品注册证书的公告 近日，山东鲁抗医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局颁发的关于注射用头孢唑肟钠（以下简称"该药品"）的《药品注册证书》 （证书编号：2025S01743、2025S01744），该药品批准注册。现将相关情况公告 如下： 一、药品证书基本信息 药品名称：注射用头孢唑肟钠 剂型：注射剂 规格：0.5g、1.0g 批准文号：国药准字 H20254488、国药准字 H20254489 药品标准：YBH12932025 注册分类：化学药品 4 类 生产企业：山东鲁抗医药股份有限公司 审批结论：本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及市场情况 头孢唑肟钠为第三代头孢菌素，具广谱抗菌作用，通过抑制细菌细胞壁粘肽 的生物合成而达到杀菌作用。对多种革兰阳性菌和革兰阴性菌产生的广谱内酰胺 酶（包括青霉素酶和头孢菌素酶）稳定 ...

Group 1 - The company received a drug registration certificate from the National Medical Products Administration for injectable Cefoperazone Sodium [1] - Cefoperazone Sodium is a third-generation cephalosporin with broad-spectrum antibacterial properties [1] - The approved registration numbers are National Drug Approval Code H20254488 and H20254489 [1] Group 2 - The company has invested approximately 2.9455 million yuan in research and development as of the announcement date [1] - The projected sales revenue for injectable Cefoperazone Sodium in Chinese urban public hospitals is expected to reach 3.078 billion yuan in 2024 [1]